Goldman Sachs lowered the firm's price target on 4D Molecular to $33 from $38 and keeps a Buy rating on the shares. 4D Molecular Therapeutics reported Q1 results and confirmed completion of randomization for its North American Phase 3 wet AMD trial of 4D-150, while reiterating global Phase 3 enrollment completion in 2H26 with data expected in 2027, the analyst tells investors in a research note. Prior Phase 1/2 results continue to support durability and tolerability, with upcoming readouts across AMD and diabetic macular edema studies and additional data on cystic fibrosis therapy 4D-710 expected in 2H, the firm says.
